Molecular beta-lactamase characterization of gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets.
Molecular beta-lactamase characterization of gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets. by Mendes RE, Castanheira M, Woosley LN, Stone GG, Bradford PA and Flamm RK published in Int. J. Antimicrob. Agents. 2018; 52 (2) 287-292
